

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

UNAUDITED FINANCIAL RESULTS OF KPC FOR THE SIX MONTHS ENDED 30 JUNE 2026

On 21 August 2026, KPC released its interim report for the six months ended 30 June 2026.

KPC Pharmaceuticals, Inc (昆藥集團股份有限公司) (“**KPC**”) is a company incorporated in the People’s Republic of China. The shares of KPC are listed on the Shanghai Stock Exchange. As of the date of this announcement, KPC is owned as to approximately 29.08% equity interest by China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”), through its non-wholly owned subsidiary, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd (華潤三九醫藥股份有限公司), and is accounted for as a subsidiary of the Company.

On 21 August 2026, KPC released its interim report for the six months ended 30 June 2026 (the “**KPC Unaudited Financials**”). Set out below are the key financial information of the KPC Unaudited Financials:

	As of 30 June 2026 (RMB) (unaudited)	As of 31 December 2025 (RMB) (audited)	Decrease (%)
Total assets	10,980,313,179.26	11,773,564,408.45	–6.74%
Net assets attributable to shareholders of the listed company	4,864,074,777.36	5,362,259,636.54	–9.29%

	For the six months ended 30 June		
	2026	2025	Decrease
	(RMB)	(RMB)	(%)
	(unaudited)	(unaudited)	
Revenue	1,643,045,313.73	3,351,347,279.45	–50.97%
Net profit attributable to the shareholders of the listed company	–363,947,613.06	198,355,219.85	–283.48%
Net profit attributable to the shareholders of the listed company (after extraordinary gains or losses)	–390,295,088.73	151,101,472.65	–358.30%
Net cash flow from operating activities	–514,027,376.61	218,830,956.35	–334.90%
Basic earnings per share (RMB/share)	–0.48	0.26	–284.62%
Diluted earnings per share (RMB/share)	–0.48	0.26	–284.62%
			decreased by 10.73 percentage points
Weighted average return on net asset	–7.03%	3.70%	

The KPC Unaudited Financials have been prepared in accordance with the PRC Generally Accepted Accounting Principles, have not been reviewed or audited by the Company's auditors, and may require adjustment during the course of auditing. The financial information is limited to KPC only and does not represent or provide a complete view of the operational or financial status of the Group. **Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.**

For further details of the KPC Unaudited Financials, please refer to the interim report for six months ended 30 June 2026 published by KPC on the website of the Shanghai Stock Exchange (www.sse.com.cn).

By order of the Board
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman

PRC, 21 August 2026

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director; Mr. Cheng Jie and Mr. Liu Changan as executive Directors; Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mdm. Zhang Jing and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive Directors.